SCHEMBL1948366

SCHEMBL1948366

CC(C)(C)OC(=O)N1CCc2cc(NCc3ccc(Cl)cc3)ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
THRB P10828 2/20 0.47
DHODH Q02127 1/20 0.46
TP53 P04637 2/20 0.46
HSP90AA1 P07900 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
MPO P05164 1/20 0.45
NOTUM Q6P988 1/20 0.44
MAPT P10636 4/20 0.44
POLB P06746 3/20 0.44
TRIM24 O15164 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
AVPR2 P30518 1/20 0.43
IDO1 P14902 1/20 0.43
HSD17B3 P37058 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2641060 0.96 LMNA (0.44) LMNATHRBDHODHTP53HSP90AA1
SCHEMBL1948851 0.92 NOTUM (0.44) LMNATHRBDHODHTP53HDAC6
SCHEMBL1948510 0.85 NOTUM (0.64) LMNATHRBTP53HSP90AA1HDAC8
SCHEMBL1950469 0.83 DRD4 (0.50) LMNATHRBTP53HSP90AA1HDAC8
SCHEMBL1948364 0.82 ESR2 (0.60) LMNATP53HTTSMN1; SMN2NPSR1
SCHEMBL27975558 0.82 NOTUM (0.65) DHODHNOTUMTRIM24AVPR2HSD17B3
SCHEMBL1950866 0.80 DRD2 (0.48) LMNATHRBTP53HSP90AA1HDAC8
SCHEMBL1950708 0.79 DRD4 (0.47) LMNATHRBTP53HSP90AA1HDAC8
SCHEMBL16920283 0.79 DHODH (0.52) DHODHTP53HDAC6MPONOTUM
SCHEMBL12464373 0.78 ALDH1A1 (0.53) LMNATP53NOTUMMAPTTRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438055-B1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS JAPAN TOBACCO INC (JP) 2018-10-24 EP disclosed
US-8426442-B2 Compounds XENTION LTD (GB) 2013-04-23 US disclosed
US-20110136860-A1 Compounds XENTION LTD. (GB) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136860-A1 Compounds NR3C2, NR5A1, NR0B2 LMNA 1298/4885THRB 315/4885DHODH 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.